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Duchenne muscular dystrophy (DMD), caused by
mutations at the dystrophin gene, is the most com-
mon form of muscular dystrophy. There is no cure
for DMD and current therapeutic approaches to
restore dystrophin expression are only partially effec-
tive. The absence of dystrophin in muscle results in
dysregulation of signaling pathways, which could
be targets for disease therapy and drug discovery.
Previously, we identified two exceptional Golden
Retriever muscular dystrophy (GRMD) dogs that
are mildly affected, have functional muscle, and
normal lifespan despite the complete absence of
dystrophin. Now, our data on linkage, whole-genome
sequencing, and transcriptome analyses of these
dogs compared to severely affected GRMD and
control animals reveals that increased expression
of Jagged1 gene, a known regulator of the Notch
signaling pathway, is a hallmark of the mild pheno-
type. Functional analyses demonstrate that Jagged1
overexpression ameliorates the dystrophic pheno-
type, suggesting that Jagged1 may represent a
target for DMD therapy in a dystrophin-independent
manner.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked disorder
caused by mutations in dystrophin (Hoffman et al., 1987), which
affects 1 in 3,500 to 5,000 boys (Axelsson et al., 2013; Mendell
et al., 2012). Deficiency of muscle dystrophin causes progres-
sive myofiber degeneration and muscle wasting (Hoffman1204 Cell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc.et al., 1987). The first symptoms are usually evident at 3–5 years
of age, with loss of ambulation between 9 and 12 years. Death
occurs in the second or third decade due to respiratory or
cardiac failure. While there are several treatments under devel-
opment or currently in use—particularly corticotherapy, which
aims to ameliorate symptoms and slow down the disease pro-
gression—there is still no cure for DMD (Bushby et al., 2010;
Guiraud et al., 2015). Allelic to DMD, Becker muscular dystrophy
(BMD) is caused by mutations that do not affect the reading
frame of the dystrophin transcript; the result is a semi-functional,
truncated dystrophin protein (Koenig et al., 1989). DMD muscle
shows a complete absence of dystrophin, whereas in the BMD
muscle there is a variable amount of partially functional dystro-
phin (Monaco et al., 1988). Differently from DMD, where most
boys carrying null mutations show a severe phenotype, BMD
patients show a variable clinical course. Genotype/phenotype
correlation studies suggest that the severity of the phenotype
is dependent on the amount of muscle dystrophin or the site
of the mutation/deletion in the dystrophin gene (Koenig et al.,
1989; Passos-Bueno et al., 1994; Vainzof et al., 1990)
DMD therapeutic approaches currently under development
aim to rescue dystrophin expression in the muscle (Fairclough
et al., 2013). Pre-clinical and clinical studies include exon-
skipping (Goemans et al., 2011; Mendell et al., 2013; van Deute-
kom et al., 2007), AAV-delivery of m-dystrophin (Mendell et al.,
2010), and nonsense suppression to induce ‘‘readthrough’’ of
nonsense mutations (Kayali et al., 2012). While AAV-delivery
led to m-dystrophin expression in skeletal muscle, T cell immunity
against dystrophin epitopes was reported (Mendell et al., 2010).
Also, the success of the dystrophin-based therapies relies on the
quality of the recipient muscle. This requires the development of
dystrophin-independent therapies to improve the muscle condi-
tion targeting the altered signaling pathways.
Toexplore theefficiencyof thedifferent therapeuticapproaches
for DMD, there is a need for animal models that mimic the human
condition. However, animal models of dystrophin-deficiency
showdifferences in skeletal muscle pathology in response to dys-
trophin-deficiency (Bassett and Currie, 2004; Chapman et al.,
1989; Im et al., 1996; Kornegay et al., 1988; Zucconi et al.,
2010). The dystrophin-deficient fish model sapje shows some
phenotypic variability, but nearly all fish die during the first weeks
of life and all show abnormal muscle structure as measured by
birefringence under polarized light (Bassett and Currie, 2004).
The mdx mouse is the most widely used animal model for DMD,
even though its mild phenotype does not mimic severe human
DMD symptoms (Bulfield et al., 1984). The most similar to the hu-
man condition is the golden retrievermuscular dystrophy (GRMD)
dog (Bassett et al., 2003; Cooper et al., 1988; Kornegay et al.,
1988; Sicinski et al., 1989). These animals carry a point mutation
on a splicing site that causes the skipping of exon 7 and a prema-
ture stop codon, resulting in the absence of dystrophin. GRMD
dogs and DMD patients share many similarities in disease patho-
genesis, including early progressive muscle degeneration and at-
rophy, fibrosis, contractures, and grossly elevated serumcreatine
kinase (CK) levels (Kornegay et al., 1988; Sharp et al., 1992). Early
death may occur within the first weeks of life but usually occurs
around 1–2 years of age as a result of respiratory failure or cardio-
myopathy. The great majority of GRMD dogs do not survive
beyond age two. In the Brazilian GRMD colony at Biosciences
Institute at the University of Sa˜o Paulo, we have described two
exceptional dogs presenting a very mild phenotype clearly distin-
guishable fromother affecteddogsdespite the absenceofmuscle
dystrophin. Histopathological and immunohistochemistry anal-
ysis of their muscle showed typical features of a dystrophic
process with variability in fiber size, splitting, degeneration, and
infiltrating connective tissue (Zucconi et al., 2010).
These two exceptional, related GRMD dogs (here called
‘‘escapers’’) remained fully ambulatory with normal lifespans,
a phenotype never reported before for GRMD. They fall outside
the known GRMD phenotypic range of variability, differing
significantly from typically affected dogs despite their dystrophic
muscle, absence of muscle dystrophin, elevated serum CK
levels, and lack of evidence of utrophin upregulation (Zatz
et al., 2015; Zucconi et al., 2010). Most importantly, these
GRMD dogs show that it is possible to have a functional muscle
in a mid-size dystrophin-deficient animal.
In this study, we set out to answer the following question: how
do these escaper dogs have a fully functional muscle without
dystrophin? Skeletal muscle of DMD patients undergoes waves
or cycles of degeneration followed by regeneration. Muscle
repair is a regulated process that comprises different cell types
and signaling molecules, but additional factors and genetic
modifiers involved in DMD pathogenesis remain poorly under-
stood, representing new potential therapeutic targets. Genetic
modifiers have been reported in DMD patients with a slower
progression, but none were associated with a nearly normal
phenotype (Flanigan et al., 2013). Here, through three indepen-
dent approaches, we identified a modifier gene, Jagged1, which
canmodulate the GRMD phenotype. Using amixedmodel asso-
ciation and linkage analysis, we identified a chromosomal region
associated with the escaper phenotype. One gene within this re-
gion showed altered expression when comparing muscle tissue
of escaper and affected dogs. By whole-genome sequencing,
we found a variant present only in escaper GRMD dogs thatCcreates a novel myogenin binding site in the Jagged1 promoter.
Overexpression of jagged1 in dystrophin deficient zebrafish
rescues the dystrophic phenotype in this zebrafish model. This
suggests that Jagged1, when increased in expression in muscle,
can rescue dystrophin-deficient phenotypes in two different
animal models, pointing to a new potential therapeutic target.
RESULTS
Escaper GRMD Dogs Share a Common Haplotype
Different from Affected
To understand the genetic basis behind the escaper phenotype
in GRMD dogs, we performed a genome-wide mapping analysis
comparing two related escaper GRMD dogs—the only two
GRMD escapers reported to date—to 31 severely affected
GRMD dogs from the same breeding population. All GRMD
dogs were confirmed to carry the originally described point mu-
tation (a change from adenine to guanine transition) in the intron
6 of the dystrophin gene. Thismutation ablates a splicing site and
exon 7 is skipped from thematuremRNA. The absence of exon 7
causes a premature stop codon at exon 8 (Cooper et al., 1988;
Sharp et al., 1992). Based on survival age and functional capac-
ity, they were classified as escaper or affected (binary). All the
dogs showing the standard range of phenotypic variability
seen in GRMD dogs were classified as affected in this study.
Our aim was to identify a single gene responsible for the milder
phenotype seen in the two escaper dogs. We performed a
two-step mapping analysis. First, we carried out an association
study, utilizing the power of the many severely affected dogs ex-
pected to lack the modifier locus. This was followed by segrega-
tion analysis, taking advantage of the fact that the two escapers
came from a well-defined pedigree in which a transmission-
based test could be used. All dogs were genotyped using the
Illumina CanineHD 170K SNP array. We tested for association
genome wide using the mixed model approach implemented in
EMMAX (Kang et al., 2010) to correct for population structure
(Figure 1A) and identified strongly associated SNPs (p <
1x105) on chromosomes 24, 33, and 37 (Figure 1B). We then
measured identity by descent (IBD) across the genome between
the two escapers using Beagle (Browning and Browning, 2007).
Only the associated SNPs on chromosome 24 also overlapped a
segment of IBD in the two escapers, consistent with a single
origin of the causative mutation (Figure 1B). The 27 Mb segment
showing both IBD and association with the escaper pheno-
type (CanFam2, cfa24:3,073,196-30,066,497) contains approxi-
mately 350 protein-coding genes. Linkage analysis using Merlin
(Abecasis et al., 2002) strongly confirmed this region, with a
maximal parametric LOD score of 3.31 (dominant inheritance
model with complete penetrance, Figure S1). No other genomic
regions showed any signs of linkage (Figure S2). Thus, conver-
gent IBD, association, and linkage analyses all pointed to the
same 27 Mb region on chromosome 24 (Figure 1C).
Muscle Gene Expression Profile of Escaper and
Affected GRMD Dogs
We then performed a genome-wide analysis for genes differ-
entially expressed in muscle between the escapers and
affected dogs. Using Agilent mRNA SurePrint Canine arrays,ell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc. 1205
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Figure 1. Combining Association, Linkage, and Identity-By-Descent Analysis Identifies a 30 Mb Candidate Region on Chromosome 24
(A) AQQplot of 129,908 SNPs tested for association identified 27 SNPs outside the 95%confidence intervals (dashed lines) andminimal stratification relative to the
expected distribution (red line), suggesting themixedmodel approach corrected for close relatedness among the 2 escapers and 31 severely affectedGRMDdogs.
(B) Only the association on chromosome 24 also falls in a region where the two escapers (sire and offspring) share a long haplotype likely to be identical-by-
descent (IBD, red). Other peaks on chromosomes 24, 33, and 37 show no evidence of IBD (gray) and are most likely false positives due to the small sample size.
(C) The mapped region extends 27 Mb from the start of chromosome 24. Linkage analysis with Merlin (solid black line) detected a significant linkage peak
(dominant parametric LOD > 3) overlapping the IBD and association peak that includes the putative driver gene jagged1 (blue line) identified through gene
expression profiling. See also Figures S1 and S2.we compared muscle gene expression of the two escapers, four
affected, and four wild-type dogs at two years of age. We found
very similar muscle gene expression patterns in the two escaper
GRMD dogs, which were more similar to muscle from wild-type
dogs than from the affected dogs. In total, 114 genes were found
to be differentially expressed between escapers and affected
GRMD dogs, as shown by unsupervised hierarchical clustering
of all ten samples (Figure 2A). Of these, 65 geneswere also differ-
entially expressed between escapers and wild-type dogs (Table
S1), implicating them in a possible compensatory mechanism
active in only the escaper dogs. Only one of these 65 genes, Jag-
ged1, is located under the association peak on chromosome 24.
Jagged1 mRNA levels were two times higher in the escapers
when compared to both wild-type and severely affected dogs
(Figure 2B). Further protein level analysis confirmed the mRNA
findings (Figure 2C).
Whole-Genome Sequence of Escaper Dogs
To identify potentially causative variants behind the differential
gene expression pattern observed in the escaper dogs, we
performed whole-genome sequencing on three dogs (the two
escapers and one severely affected related dog). We hypothe-
sized that the compensatory variation would be novel, as the
escaper phenotype had not previously been seen in GRMD1206 Cell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc.dogs worldwide. We looked for variants located under the
association peakonchromosome24and focusedon the Jagged1
locus (including 3 KB upstream and downstream of the gene) in
search for a variant present only in the escapers and not in the
affected GRMD dogs. A total of 1,300 variants were detected
within the escaper-associated region on chromosome 24. All
variants were lifted over to the human genome, and those present
inmuscleenhancer regionsnear thepromotersof the two isoforms
of Jagged1 expressed in skeletal muscle (Figure 3A) (Hoeppner
et al., 2014) were further analyzed. Since the escaper variant
was hypothesized to be novel, all variants detected in previous
extensive canine sequencing efforts (Axelsson et al., 2013) were
excluded. After this filtering, only a single point variant was found
to follow theescaper haplotype: a heterozygoteG>Tchange in the
promoter region of Jagged1 (cfa24:11655709, Figure 3A). Sanger
sequencing of the Jagged1 candidate escaper variant was per-
formed in the escaper extended pedigree, including the first
escaper (M1M4), his offspring, and a sibling’s offspring (M1M5)
(Figure S3). We also sequenced key breeders of the kennel and
found that the variant is specific to the escapers’ pedigree and
was introduced in a single outcross (B1F3 mate). All affected
dogs lacked the Jagged1 variant, while both escapers were het-
erozygous. Thus, the novel Jagged1 mutation segregates with
the escaper phenotype in this family. Four additional individuals
AB
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Figure 2. Altered Jagged1 Expression in Escaper GRMD Dogs
(A) mRNA microarray comparing muscle gene expression of escaper GRMD
dogs with related severely affected and WT dogs.
(B) mRNA expression of escaper dogs confirming the expression array find-
ings. Relative Jagged1 gene expression in muscle samples of escaper GRMD
dogs as compared to related severely affected andWT dogs; bars indicate SD
from the mean.
(C) Jagged1 protein levels in the muscle of escaper GRMD dogs (E) as
compared to severely affected (A) and WT dog muscle (N); Beta-actin is the
loading control. See also Table S1.
Ccarried the candidate variant: threewere stillborn puppies and the
fourth was a GRMD puppy that died at 6 months of age from an
accidental ingestion of a foreign object. This puppy (K2M11) was
fully ambulatory with a similar phenotype to the two escaper
dogs, but he was classified as affected in the mapping analysis
since we cannot predict his adult phenotype with confidence.
Functional Analysis of Jagged1 Variant
To understand the effects of the escaper variant, we performed
different functional analyses. This candidate variant was found
tobe conserved across29eutherianmammals, suggesting a reg-
ulatory potential for this region (Figures 3A and 3B). Transcription
factor binding site analysis, using TRAP (Manke et al., 2010) and
TRANSFAC (Matys et al., 2006), revealed that this G>T change
creates a novel myogenin binding site (Figure 3C) with a high
information content for the mutant allele (T) in the myogenin
consensus binding motif (Figure 3D). Myogenin is a muscle-spe-
cific transcription factor involved in muscle differentiation and
repair (Wright et al., 1989). To determine whether the variant af-
fects DNA binding by myogenin, we carried out electrophoretic
mobility shift assays (EMSAs) using muscle cell nuclear extracts
and biotin-labeled oligonucleotide probes containing either
the wild-type (WT) or escaper (E) genotype. The oligonucleotide
probe containing the escaper T allele robustly bound the myoge-
nin protein, whereas an oligonucleotide probe containing the WT
Gallele didnotbindat all (Figure3E). A competitionassayshowed
that an unlabeled escaper probe efficiently competed with the
binding of the labeled escaper probe. In contrast, the unlabeled
WT probe had no effect on the binding activity of the labeled
escaper probe, indicating a specific interaction between the
escaper allele and myogenin (Figure 3E). To evaluate whether
the novel myogenin binding site found in the escaper dogs was
driving the increased expression of Jagged1, we performed a
luciferase reporter assay using Jagged1 upstream promoter
sequences containing either the WT sequence or the escaper
variant fused to a luciferase reporter. Luciferase vectors contain-
ing either WT or escaper sequence were transfected into muscle
cells (myoblasts) and human embryonic kidney cells (HEK293T)
along with constructs that overexpress either myogenin or
another E-box myogenic factor (MyoD) as control. On HEK293K
cells, overexpression of myogenin was able to activate the
expression of the escaper Jagged1 reporter 3-fold, but showed
no activation of the WT reporter (Figure 3F). As predicted, the
overexpression ofMyoDdid not activate either theWTor escaper
Jagged1 luciferase reporter (Figure 3F). Similarly, myoblasts (that
endogenously express myogenin) transfected with the escaper
vector showed a similar luciferase activation that was three times
higher than the WT vector, notwithstanding the presence of
overexpression vectors (Figure 3F). These results demonstrate
that the creation of the novelmyogenin binding site in the escaper
Jagged1promoter is essential for driving the increase of Jagged1
expression in the escaper dog skeletal muscles.
In Vivo Overexpression of Jagged1 Rescues sapje
Muscle Phenotype
To evaluate if the overexpression of Jagged1 can ameliorate the
dystrophic muscle phenotype in other species, we used the
severely affected dystrophic sapje zebrafish DMD model.ell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc. 1207
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Figure 3. Variant Located in the Jagged1 Promoter of Escaper GRMD Dogs
(A) Dog and Human Jagged1 locus. Box: variant at dog chr24:11,644,709.
(B) Conservation of the variant position.
(C) Predicted transcription factor binding site at the region with the base pair change.
(D) Consensus sequence of myogenin binding site, demonstrating the high information content of the T allele.
(E) Electromobility shift assay (EMSA) showing myogenin binding to mutated probe (E) and not to the WT probe.
(F) Luciferase reporter assay showing activity of WT and E genotype vectors in both muscle cells (C2C12) and embryonic kidney cells (293T) with Myogenin or
MyoD overexpression, as compared to empty vectors controls (V). Error bars indicate SEM (n = 3 replicates). See also Figure S3.Muscle phenotype was assayed using birefringence, where fish
are placed under a polarized light and dystrophin-negative fish
show a decrease in the amount of light, indicative of muscle1208 Cell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc.tearing or muscle fiber disorganization. In four separate experi-
ments, we injected approximately 200 fertilized one-cell stage
eggs from sapje heterozygous fish matings with mRNA of either
A B
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Figure 4. Functional Analysis of jagged1
Expression
(A) Percent affected sapje fish as determined by
birefringence assay at 4 dpf. Note fewer affected
fish in the jagged1 injected sapje cohort. Four
separate injection experiments were performed.
(B) Genotype of sapje injected fish with jagged1a
and jagged1b as compared to non-injected
sapje fish. In red are dystrophin-null fish with a WT
phenotype, recovered by jagged1 overexpression.
(C) Immunofluorescence of jagged1a and jagged1b
overexpression in the sapje fish. WT, phenotypi-
cally affected homozygous fish for the dystrophin
mutation and jagged1a and jagged1b injected with
normal birefringence (recovered) were stained for
myosin heavy chain (MCH) and dystrophin anti-
bodies. Note the organization of the muscle fibers
in the recovered fish muscle comparable to the WT
fish (n = 10) even without dystrophin. Photographs
were taken at 20x magnification.
(D) Jagged1 protein levels in the muscle of car-
diotoxin injured mice one, four, and seven days
after injury.
(E) Jagged1 protein levels in muscle cells during
in vitro muscle differentiation.
(F) Muscle cell proliferation rate, as measured by
MTT, of two WT, two escaper, and two affected
GRMD dogs. Error bars indicate SEM (n = 2, three
replicates).one of the zebrafish jagged1 genetic copies of the mammalian
Jagged1 gene: jagged1a or jagged1b. In all experiments, an
average of 24% of the non-injected sapje fish exhibited a typical
affected dystrophic, patchy birefringence phenotype. This pro-
portion is within the 21%–27% expected range of affected
fish of a heterozygous sapje mating. In contrast, fish injected
with either jagged1a or jagged1b showed a significantly lower
percentage of fish with poor birefringence (p = 1.313106 for
jagged1a, p = 4.43105 for jagged1b, Figure 4A). Genotypic
analysis revealed that about 75% of dystrophin-null fish injected
with jagged1a and 60% of of those injected with jagged1b had
normal birefringence, which demonstrated a common rescueCell 163, 1204–1213, Nfrom the muscle lethality phenotype (Fig-
ure 4B). These results indicate that
increasing jagged1 expression rescues
most dystrophin-null fish from developing
the abnormalities typically seen in dystro-
phin-null muscle. To further evaluate the
jagged1a and jagged1b overexpression
sapje fish, we performed immunostaining
on individual fish bodies using a myosin
heavy chain (MHC) antibody to evaluate
muscle structure. In WT fish, MHC was
clearly expressed and showed that mus-
cle fibers were normal. Interestingly,
MHC staining of jagged1 mRNA-injected
dystrophin-null rescued fish showed
normal myofiber structure similar to that
of WT fish, whereas affected, non-injecteddystrophin-null fish demonstrated clear muscle abnormalities
(Figure 4C).
Jagged1 Expression during Muscle Regeneration and
Cell Proliferation in Mice and Dogs
When examining the effect of Jagged1 onmuscle regeneration in
normal mice, we found that Jagged1 expression is upregulated
at day 4 after cardiotoxin-induced injury in mouse tibialis anterior
muscle (Figure 4D).We also determined that Jagged1 is elevated
during myoblast muscle differentiation in vitro (Figure 4E). To
examine whether muscle cells from escaper dogs proliferate
faster than cells from severely affected dogs, we performed aovember 19, 2015 ª2015 Elsevier Inc. 1209
proliferation assay using myogenic cells from biopsies of age-
matched dogs. Escaper dogs’ muscle showed typical dystro-
phic features (Zucconi et al., 2010) as evidenced by cycles
of degeneration and regeneration, which is not seen in normal
muscle. Because of these cycles and consistent activation,
myogenic cells from affected GRMDdogs are expected to divide
less frequently. We show that muscle cells from escaper dogs
divide significantly faster than those from affected dogs (Fig-
ure 4F). These results are consistent with previous findings that
show that overexpression of the Notch intracellular domain
(NICD) expands the proliferative capacity of activated muscle
satellite cells in vitro and in vivo (Wen et al., 2012).
DISCUSSION
Animal models for DMD are important tools for developing new
therapeutic approaches. Among the different animal models
for muscular dystrophy, the GRMD dog is the closest to the
human condition. Both GRMD dogs and DMD patients have
a severe phenotype as well as many phenotypic and biochem-
ical similarities, including early progressive muscle degenera-
tion and atrophy, fibrosis, contractures, and elevated serum
creatine kinase levels. We identified two dogs that escaped
from the typical severe phenotype associated with dystrophin
deficiency. Using a combined approach of mapping and
identity by descent, we identified a candidate region of associ-
ation with the escaper phenotype. Only one gene within this
region showed altered expression in escaper and affected
dogs: Jagged1. We found a candidate variant at an upstream,
conserved position creating a new muscle-specific transcrip-
tion factor binding site that drives Jagged1 overexpression.
Jagged1 is also in the region associated to the mild pheno-
type observed in a muscular dystrophy mouse model on the
MRL (Murphy Roths Large) ‘‘superhealing’’ background. These
mice show enhanced muscle regeneration and reduced
dystrophic pathology. This healing phenotype was mapped
to a region containing 49 genes that includes the Jagged1 lo-
cus (Heydemann et al., 2012).
The role of Jagged1 in skeletal muscle development and dis-
ease has yet to be fully elucidated. Jagged1 is a Notch ligand
(Lindsell et al., 1995). The Notch signaling pathway represents
a central regulator of gene expression and is critical for cellular
proliferation, differentiation, and apoptotic signaling during all
stages of embryonic muscle development. The Notch pathway
also plays an important role in muscle regeneration (Conboy
andRando, 2002;Wen et al., 2012), and overexpression ofNotch
has been shown to improve muscle regeneration in aged mice
(Conboy et al., 2003). Moreover, Notch signaling has been
shown to be dysregulated in muscle satellite cells and dystro-
phin-deficient muscles frommdxmice (Jiang et al., 2014). Addi-
tionally, there is an even more pronounced dysregulation of
Notch signaling in the muscle satellite cell in the severemdx/utrn
double knockout mice (dKO) that have early lethality at two to
four months due to a breakdown of the diaphragm muscles
(Church et al., 2014; Mu et al., 2015). Here, we observed greater
proliferative capacity of the escaper dogs’ myoblasts, suggest-
ing that Jagged1 overexpression might be involved in muscle
cell proliferation and repair. These results are consistent with1210 Cell 163, 1204–1213, November 19, 2015 ª2015 Elsevier Inc.previous findings, which demonstrate that Jagged1 overexpres-
sion stimulates cell proliferation, suggesting that Jagged1-based
therapy might be able to induce regeneration in a tissue-specific
manner (Collesi et al., 2008). Our data show that Jagged1
expression is upregulated at day 4 after cardiotoxin-induced
injury in mouse, a time point when myoblasts proliferate and
fuse to promote muscle regeneration (Couteaux et al., 1988).
Furthermore, Jagged1/Notch signaling has been shown to
promote the expansion and differentiation capacity of bone
marrow-derived stromal/stem cells (BMSCs) to promote skeletal
regeneration (Dong et al., 2014). In endothelial cells, genetic
Jagged-1 overexpression resulted in endothelial branching of
vasculature processes; while conversely, Jagged-1 endothelial
deletion blocked angiogenic growth in Jagged-1 eKO mice (Pe-
drosa et al., 2015). Indeed, Jagged-1 overexpression leads to the
activation of vasculature progenitor cells from quiescence, in a
manner similar to that of muscle satellite cell activation (Ottone
et al., 2014). Thus, it is likely that the endogenous overexpression
of Jagged-1 that occurs in the muscles of the escaper dogs is
driving myogenic cell proliferation and potential muscle growth
that occurs in mesodermal lineages. A proof-of-principle exper-
iment in which the Notch downstream transcription factor Rbp-jk
was deleted in muscle satellite cells demonstrated that inhibition
of Notch activation was detrimental to both muscle growth and
muscle satellite cell expansion (Bjornson et al., 2012). All these
findings suggest that Jagged1 is likely to be a mediator of the
regenerative process that is disrupted in dystrophin-deficient
muscles and has potential as a novel therapy target to mitigate
DMD pathological progression.
Although the great majority of DMD patients show a severe
course, exceptional cases of dystrophin-deficient patients with
a milder phenotype have been identified. We have previously
reported two patients carrying null mutations, with no skeletal
muscle dystrophin present via immunofluorescent staining or
western blot analysis, and a milder course including the mainte-
nance of ambulation well into their second decade of life (Zatz
et al., 2014). More recently, a dystrophin-negative patient who
remained ambulant until age 30 was also reported (Castro-
Gago, 2015). Several other genetic modifiers are known to affect
the severity of the clinical symptoms of Duchenne muscular dys-
trophy (LTBP4, SPP1, TGFBR2). However, none of these genetic
variants have been shown to fully restore or delay substantially
the symptoms of dystrophin-deficiency in DMD boys (Bello
et al., 2012; Flanigan et al., 2013; Pegoraro et al., 2011; Piva
et al., 2012). Furthermore, it would be of great interest to examine
the genomes of DMD boys with varying clinical symptoms
and determine if variants in Jagged1 or other Notch signaling
factors exist and are causative for any variation of the dystrophic
disease progression. The Notch signaling pathway, specifically
Jagged1 overexpression, represents a novel therapeutic entry
point for the treatment of DMD. Full restoration of Notch
signaling must be achieved in the muscle satellite cell if one ex-
pects to correct the dysregulated Notch-dependent signaling
that is affected in dystrophin-deficiency (Church et al., 2014).
Direct injection of exogenous, soluble Jagged-1 ligand is not a
viable therapeutic option, as external Jagged1 weakens Notch
signaling even more than dystrophin-deficiency (Xiao et al.,
2013). Thus, one might envision finding a small molecule or
transcription factor that could increase expression of Jagged1 in
all of the skeletal muscles of DMD patient.
There is currently no cure for DMD, and existing therapies
aiming to rescue dystrophin expression are only partially effec-
tive. Here, we show that the overexpression of Jagged1 is likely
to modulate the dystrophic phenotype in dystrophin-deficient
GRMD dogs. We also show that overexpression of jagged1 res-
cues the dystrophic phenotype in a severe DMDmodel: the sapje
zebrafish. Our study highlights the possibilities of across-spe-
cies analysis to identify and validate disease-modifying genes
and associated pathways. These results suggest that Jagged1
may be a new target for DMD therapeutic efforts in a dystro-
phin-independent manner, which will complement existing ap-
proaches. In addition, further investigation on the gene target
Jagged1 will contribute to a better understanding of the disease
pathogenesis and molecular physiology.EXPERIMENTAL PROCEDURES
GRMD dogs were classified for this study in two groups based on full ambula-
tory capacity and survival age. The escapers group included the GRMD dogs
that were fully ambulatory (can walk and run) at 9 years old. One escaper dog
(M1M4) died at 11 years old from a cardiac arrest (Zatz et al., 2015) and the
second one (H3M10) is now 9.5 years old and shows full ambulation. The
affected group included the GRMD dogs that died before 5 years old with
ambulatory difficulties, respiratory failure, and cardiopathy; this group includes
stillbirths, neonatal death, and one dog that was full ambulatory when he died
by ingesting a foreign object at 6-months-old (K2M11); all were confirmed to
carry the GRMD mutation. DNA from GRMD dogs with and without the
escaper phenotype was genotyped using the Illumina canine 170,000 SNP
array and was compared using association, linkage, and IBD mapping. The
threshold for genome-wide significance for each association analysis was
defined based on the 95% confidence intervals (CIs) calculated from the
beta distribution of observed p values, as previously described (Wellcome
Trust Case Control, 2007). The likelihood of the two escapers being identity
by descent (IBD) at each SNP was estimated based on haplotype frequencies
in the full pedigree using Beagle 4 (release v4.r1274) with default parameter
settings (Browning and Browning, 2007). Linkage analysis was performed
using MERLIN (Abecasis et al., 2002) 1.1.2 to first remove inconsistent geno-
types and then calculate LOD scores (logarithm of the odds ratios) using a
dominant parametric model with complete penetrance. Expression analysis
from the same dogs was performed using two-color microarray-based gene
expression analysis. Genes differentially expressed between WT, escaper,
and affected animals were identified with the significance analysis of microar-
ray (SAM) statistical approach. False discovery rate (FDR) was 5%. Whole-
genome sequencing was performed to 30x depth of three dogs (two escapers
and one affected dog). Samples were sequenced on an Illumina HiSeq 2000,
and sequencing reads were aligned to the CanFam 3.1 reference sequence
using BWA. Following GATK base quality score recalibration, indel realign-
ment, and duplicate removal, SNP and INDEL discovery was performed. To
assess myogenin binding to candidate mutation, EMSA was performed using
biotin labeled or unlabeled competitors probes and the LightShift Chemolumi-
nescent EMSA kit (Thermo Scientific) following manufacturer’s instructions.
Luciferase reporter assay was performed cloningWT andGRMDdog Jagged1
promoter region containing the G>T change into the pIRES-2a-hrGFP expres-
sion plasmid (Stratagene). HEK293T or C2C12 cells were transfected with
affected or escaper 30UTR jagged1-luc reporter constructs,Myogenin or
MyoD overexpression plasmid, and renilla as internal control. Cells were lysed
and assayed with luciferase substrate using the Dual Reporter Assay (Prom-
ega). Luciferase measurements were normalized to the renilla luciferase con-
trol on each well. Zebrafish were used for jagged1 overexpression assay,
where fertilized one-cell stage eggs from a sapje heterozygous fish mating
were injectedwithmRNA from either one of the zebrafish jagged1 gene copies:
jagged1a or jagged1b. Zebrafish injected with either mRNA or non-injectedCcontrols were assessed for phenotypic changes at 4 days post-fertilization
(4dpf). Methods for cell growth assay and cardiotoxin injury are described in
Supplemental Experimental Procedures
Supplemental Experimental Procedures are available as supplemental
materials.
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